Uveitis in seronegative arthritis

Current Rheumatology Reports

Volumn 14, Issue 5, 2012, Pages 402-408

  Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

HLA B27; IL 17; Interleukin 17; Pathophysiology; Seronegative arthritis; Spondyloarthritis; TNF; Treatment; Tumor necrosis factor; Uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 23; INTERLEUKIN 27; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

CYTOKINE RESPONSE; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERITIS; GENETIC ASSOCIATION; GRAM NEGATIVE INFECTION; HUMAN; IRIDOCYCLITIS; KIR GENE; NONHUMAN; PREVALENCE; REFRACTORY UVEITIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLARTHRITIS; TH17 CELL; TLR GENE; TREATMENT OUTCOME; UVEITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL AGENTS; BIOLOGICAL FACTORS; CLINICAL TRIALS AS TOPIC; HLA-B27 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; RHEUMATOID FACTOR; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 84869238810     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0267-1     Document Type: Review

References (47)

1. Munoz-Fernandez S, Martin-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006; 20: 487-505. (Pubitemid 43843070)
2. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008; 67: 955-9. (Pubitemid 351956657)
3. Sampaio-Barros PD, Conde RA, Bonfiglioli R, Bé rtolo MB, Samara AM. Characterization and outcome of uveitis in 350 patients with spondyloarthropathies. Rheumatol Int. 2006; 26: 1143-6. (Pubitemid 44450852)
4. Linder R, Hoffmann A, Brunner R. Prevalence of the spondyloarthritidies in patients with uveitis. J Rheumatol. 2004; 31: 2226-9.
5. Monnet D, Breban M, Hudry C, Dougados M, Bré zin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology. 2004; 111: 802-9. (Pubitemid 38429680)
6. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68: 777-83.
7. Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brand J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011; 70: 25-31.
8. Chung YM, Liao HT, Lin KC, Lin YC, Chou CT, Chen CH, Tsai CP. Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27-associated acute anterior uveitis. Scand J Rheumatol. 2009; 38: 84-90.
9. Muñ oz-Ferná ndez S, de Miguel E, Cobo-Ibá ñ ez T, Madero R, Ferreira A, Hildago MY, et al. Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis. Arthritis Rheum. 2009; 60: 1985-90.
10. Chen CH, Lin KC, Chen HA, Liao HT, Liang TH, Wang HP, Chou CT. Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol. 2007; 26: 953-7.
11. Canouï -Poitrine F, Kemta Lekpa F, Farrenq V, Boissinot V, Hacquardo-Bouder C, Comet, D, et al. Prevalence and factors associated with uveitis in spondyloarthropathies patients in France: Results from the EXTRA observational survey. Arthritis Care Res (Hoboken). 2012 Jan 19. doi: 10.1002/acr.21616. A nationwide cross-sectional study of uveitis in spondyloarthritis patients, with confirmation of the high prevalence of uveitis in this condition and its relation with HLA-B27 and disease duration.
12. Dougados M, d'Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudepierre P, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine. 2011; 78: 598-603.
13. Wendling D, Prati C, Demattei C, Miceli C, Daures JP, Dougados M. Impact of uveitis on the phenotype of patients with recent inflammatory back pain. Data from the DESIR cohort. Arthritis Care Res (Hoboken). 2012 Feb 21. doi: 10.1002/acr.21648. First data about uveitis in this prospective cohort of potential early spondyloarthritis, uveitis being associated in this population with recent infectious episode and inflammatory bowel disease.
14. Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res. 2012; 31: 182-94. Clear description of the several immunological pathways involved in the development of noninfectious uveitis.
15. Wakefield D, Chang JH, Amjadi S, Maconochie Z. Abu El-Asrar A, McCluskey P. What is new HLA-B27 acute anterior uveitis? Ocul Immunol Inflamm. 2011; 19: 139-44.
16. Chavan H, Samant R, Deshpande A, Mankeshwar R. Correlation of HLA B27 subtypes with clinical features of ankylosing spondylitis. Int J Rheum Dis. 2011; 14: 369-74.
17. El-Shabrawi Y, Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, et al. Polymorphisms within the tumor necrosis factoralpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations. Ophthalmology. 2006; 113: 695-700.
18. Pratap DS, Lim LL, Wang JJ, Mackey DA, Kearns LS, Stawell RJ, et al. The role of toll-like receptor variants in acute anterior uveitis. Mol Vis. 2011; 17: 2970-7.
19. Levinson RD, Martin TM, Luo L, Ashouri E, Rosenbaum JT, Smith JR, et al. Killer cell immunoglobulin-like receptors in HLA-B27- associated acute anterior uveitis, with and without axial spondyloarthropathy. Invest Ophthalmol Vis Sci. 2010; 51: 1505-10.
20. Dí az-Peñ a R, Blanco-Gelaz MA, Ló pez-Larrea C. KIR genes and their role in spondyloarthropathies. Adv Exp Med Biol. 2009; 649: 286-99.
21. Jung KH, Kim TH, Sheen DH, Lim MK, Lee SK, Kim JY, et al. Associations of vitamin d binding protein gene polymorphisms with the development of peripheral arthritis and uveitis in ankylosing spondylitis. J Rheumatol. 2011; 38: 2224-9.
22. Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int. 2010; 30: 1547.
23. Rosenzweig HL, Galster K, Vance EE, Ensign-Lewis J, Nunez G, Davey MP, Rosenbaum JT, et al. NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2011; 52: 4106-12.
24. Kezic JM, Glant TT, Rosenbaum JT, Rosenzweig HL. Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther. 2012; 14(1): R18.
25. Oh K, Byoun OJ, Ham DI, Kim YS, Lee DS. Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation. Eur J Immunol. 2011; 41: 392-402.
26. Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010; 91: 162-70.
27. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One. 2012; 7: e29742.
28. Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL. Interferon-γ regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis. Arthritis Rheum. 2012; 64: 762-71.
29. Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann Rheum Dis. 2012 Jan 20. [Epub ahead of print]
30. Onal S, Kazokoglu H, Incili B, Demiralp EE, Yavuz S. Prevalence and levels of serum antibodies to gram negative microorganisms in Turkish patients with HLA-B27 positive acute anterior uveitis and controls. Ocul Immunol Inflamm. 2006; 14: 293-9. (Pubitemid 44627587)
31. Muñ oz-Ferná ndez S, Hidalgo V, Ferná ndez-Meló n J, Schlincker A, Bonilla G, Ruiz-Sancho D, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol. 2003; 30: 1277-9. (Pubitemid 36666354)
32. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañ ares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond). 2000; 14(Pt 3A): 340-3. (Pubitemid 30479708)
33. Muñ oz-Ferná ndez S, Garcí a-Aparicio AM, Hidalgo MV, Platero M, Schlincker A, Bascones ML, et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye (Lond). 2009; 23: 1130-3.
34. Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm. 2010; 18: 116-20.
35. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005; 52: 2447-51. (Pubitemid 41117431)
36. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, Dougados M. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006; 65: 1631-4. (Pubitemid 44799677)
37. Rudwaleit M, Rø devand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H.Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009; 68: 696-701.
38. Sieper J, Koenig A, Baumgartner S, Wishneski C, Foehl J, Vlahos B, Freundlich B. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis. 2010; 69: 226-9. A systematic analysis of the literature concerning the frequency of uveitis in the clinical trials with etanercept.
39. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007; 56: 3248-52. (Pubitemid 47585419)
40. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume- Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011; 41: 503-10. A nationwide study of the cases of new onset uveitis in anti TNF treated patients with rheumatologic condition, in comparison with the number of exposed patients for each condition.
41. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011; 50: 1390-4.
42. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011; 11: 35-9.
43. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010; 62: 821-5.
44. Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011; 19: 382-3.
45. Wendling D, Dernis E, Prati C, Frisch E, Delbosc B. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011; 38: 2284.
46. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010; 2(52): 52ra72.
47. Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde D. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis. Ann Rheum Dis. 2012 Jan 30. [Epub ahead of print]